Viracta Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 18/240,853 titled "HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)"
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics has received a Notice of Allowance for its U.S. Patent Application 18/240,853 titled 'HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)'.
August 09, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viracta Therapeutics has received a Notice of Allowance for its U.S. Patent Application 18/240,853, which covers HDAC Inhibitor Solid State Forms for treating cancer, immune disorders, and inflammation.
The Notice of Allowance for the patent application is a positive regulatory development for Viracta Therapeutics. It strengthens the company's intellectual property portfolio and could enhance its market position in treating cancer, immune disorders, and inflammation. This news is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100